טוען...
The thromboprotective effect of bortezomib is dependent on the transcription factor Kruppel-like factor 2 (KLF2)
Multiple myeloma confers a high risk for vascular thrombosis, a risk that is increased by treatment with immunomodulatory agents. Strikingly, inclusion of the proteasome inhibitor bortezomib reduces thrombotic risk, yet the molecular basis for this observation remains unknown. Here, we show that bor...
שמור ב:
| Main Authors: | , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
American Society of Hematology
2014
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4055929/ https://ncbi.nlm.nih.gov/pubmed/24771858 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-01-547448 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|